Tempest Therapeutics, Inc.

NasdaqCM:TPST Stock Report

Market Cap: US$75.1m

Tempest Therapeutics Past Earnings Performance

Past criteria checks 0/6

Tempest Therapeutics's earnings have been declining at an average annual rate of -15.3%, while the Biotechs industry saw earnings growing at 14.5% annually.

Key information

-15.3%

Earnings growth rate

73.5%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth raten/a
Return on equity-144.2%
Net Marginn/a
Last Earnings Update31 Mar 2024

Recent past performance updates

No updates

Recent updates

Tempest Therapeutics GAAP EPS of -$0.79

Aug 15

Tempest Therapeutics CEO Stephen Brady - Small Molecule Cancer Treatment

Jan 04

Revenue & Expenses Breakdown
Beta

How Tempest Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:TPST Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 240-301217
31 Dec 230-291217
30 Sep 230-311119
30 Jun 230-331221
31 Mar 230-351222
31 Dec 220-361223
30 Sep 220-341221
30 Jun 220-341220
31 Mar 220-311119
31 Dec 210-281017
30 Sep 210-25915
30 Jun 210-22715
31 Mar 210-20515
31 Dec 200-19514

Quality Earnings: TPST is currently unprofitable.

Growing Profit Margin: TPST is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TPST is unprofitable, and losses have increased over the past 5 years at a rate of 15.3% per year.

Accelerating Growth: Unable to compare TPST's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TPST is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).


Return on Equity

High ROE: TPST has a negative Return on Equity (-144.24%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.